OCULAR THERAPEUTIX, INC (OCUL)
OCULAR THERAPEUTIX, INC (OCUL) from its SEC filings: 2025 revenue $52.0 million (-18% vs the year before), net margin -512%, free cash flow -$216.9 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $52.0 million |
| Revenue growth | -18% |
| Net income | -$265.9 million |
| Net margin | -511.9% |
| Free cash flow | -$216.9 million |
| Diluted EPS | $-1.42 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +0% |
| Cash | $598.6 million |
| Long-term debt | $18.0 million |
| Share count, 1 year | +26% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.